Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : RA Capital Management
Deal Size : $200.0 million
Deal Type : Series C Financing
Abcuro Secures $200M Series C to Advance Inclusion Body Myositis Drug
Details : The Proceeds will used to support the completion of the registrational Phase 2/3 MUSCLE trial of ABC008 (ulviprubart) in inclusion body myositis, BLA filing, and commercial launch preparation.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
February 12, 2025
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : RA Capital Management
Deal Size : $200.0 million
Deal Type : Series C Financing
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 10, 2024
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Redmile Group
Deal Size : $155.0 million
Deal Type : Series B Financing
Details : Abcuro will use the proceeds from the financing to complete a Phase 2/3 registrational clinical trial evaluating ABC008, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of inclusion body myosi...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
August 17, 2023
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Redmile Group
Deal Size : $155.0 million
Deal Type : Series B Financing
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABC008 is a first-in-class anti-KLRG1 antibody, designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM), T cell large granular lymphocytic leukemia (T-LGLL), and mature T cell...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABC008 is a first-in-class anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, while sparing regulatory and central memory T cells.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 04, 2023
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABC008
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 10, 2023
Lead Product(s) : ABC008
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABC008
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 08, 2022
Lead Product(s) : ABC008
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulviprubart
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABC008 is a first-in-class anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, while sparing regulatory and central memory T cells.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 10, 2022
Lead Product(s) : Ulviprubart
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Mass General Brigham Ventures
Deal Size : $42.0 million
Deal Type : Series A Financing
Abcuro Raises $42 Million in Series A-1 Financing
Details : Proceeds from this financing will be used to advance ABC008, an anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy tissue in a variety of autoimmune diseases.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
July 01, 2021
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Mass General Brigham Ventures
Deal Size : $42.0 million
Deal Type : Series A Financing
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABC008 is an anti-KLRG1 antibody capable of selectively depleting subpopulations of highly cytotoxic, tissue-damaging, late-differentiated effector memory (TEM) and effector (TEMRA) T cells for treatment of inclusion body myositis (IBM), an autoimmune di...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 10, 2021
Lead Product(s) : Ulviprubart
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable